Search Results

BioDirection®, Inc. d/b/a NanoDiagnostics TM , Inc. (NanoDx TM ), a privately held medical device company developing cutting-edge and rapid point-of-care in-vitro diagnostic products for the objective detection, diagnosis and management of Traumatic Brain Injury (TBI), virus detection and inflammatory disease today announced that it has closed a

BioDirection, Inc., a privately held medical device company developing cutting-edge and rapid point-of-care products for the objective diagnosis and management of concussion and other traumatic brain injuries, today announced that Jean-Luc Boulnois has joined the company’s Board of Directors.

BioDirection, Inc., a privately held medical device company developing cutting-edge and rapid point-of-care products for the objective diagnosis and management of concussion and other traumatic brain injuries, today announced that the company has leased a 5,000 sq. ft. facility in Southborough, Massachusetts for its new corporate headquarters.

BioDirection, Inc., a privately held medical device company developing cutting-edge and rapid point-of-care products for the diagnosis and management of concussions and other acquired traumatic brain injuries, today announced that Sharad H. Joshi has joined the company as President and Chief Executive Officer (CEO).

BioDirection, Inc., a privately held medical device company developing cutting-edge and rapid point-of-care products for the objective diagnosis and management of concussion and other acquired traumatic brain injuries, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s Tbit™ System for the prediction of positive computerized tomography (CT) scans following Traumatic Brain Injury (TBI).

Massachusetts based Biodirect and Boston Microscopes along with California based BioSurplus today announced the completion of a merger to form Copia Scientific, to be based in Massachusetts.

Facility to manufacture key nanosensor component of the Tbit™ System

Ultra-sensitive proprietary nanowire technology positioned to provide global physicians with new tool for diagnosis of traumatic brain injury and inflammatory disease

Proprietary nanowire technology to be evaluated as potential diagnostic platform for measuring inflammatory biomarkers associated with bacterial infection affecting 30 million people worldwide